Dublin, Aug. 16, 2024 (GLOBE NEWSWIRE) — The “Preeclampsia Diagnostics Market – Forecasts from 2024 to 2029” report has been added to ResearchAndMarkets.com’s offering.
The prevalence of preeclampsia in expectant mothers is prompting a steady growth in the global preeclampsia diagnostics market. According to recent market analysis, this sector is anticipated to flourish at a CAGR of 2.60% from its valuation of US$1.012 billion in 2022, reaching US$1.211 billion by the year 2029.
At the forefront of this market’s expansion is the increased incidence of preeclampsia worldwide, necessitating precise diagnostic solutions. Preeclampsia, characterized by high blood pressure and signs of damage to other organ systems, most often the liver and kidneys, stands as a leading cause of maternal and fetal morbidity and mortality. This has heightened the demand for early and accurate detection through diagnostic tests.
Medical professionals stress the importance of prompt and precise diagnostics in managing preeclampsia, which presents multiple risks to both mothers and babies. Early birth associated with preeclampsia treatment can lead to neonatal complications, while untreated preeclampsia may result in severe health consequences, spurring the need for sophisticated diagnostic tools. Enhancement through Technological Advancements
The market is witnessing significant technological developments in healthcare, which are improving the precision of preeclampsia testing. These advancements facilitate timely and effective risk assessment and enhance patient management, driving the growth of the preeclampsia diagnostics market.
Efforts to Boost Awareness and Diagnostic Accessibility
Government initiatives and awareness campaigns are playing a pivotal role in educating about preeclampsia, ultimately influencing the diagnostics market. Notable efforts to enhance public knowledge and encourage diagnostic testing have been critical in addressing this health challenge.
Regional Market Outlook: North America in Focus
North America is poised to maintain a dominant position in the preeclampsia diagnostics market. Factors contributing to this include an uptick in regional preeclampsia cases, rising public awareness, and the presence of key market players that drive innovation and offer state-of-the-art testing solutions.
Industry Participants and Innovations
The market comprises numerous participants engaged in the development and delivery of various diagnostic tools and services. Recent developments in the sector include the introduction of new diagnostic tests and collaborations aimed at enhancing predictive models for preeclampsia.
Market Segmentation Overview
The preeclampsia diagnostics market is segmented by test type, products and services, and end-user, further detailed by geography into regions such as North America, Europe, Asia Pacific, the Middle East and Africa, and South America. This segmentation provides insight into the sector’s varied aspects, driven by regional and global health trends. Through continuous research and development, and bolstered by robust awareness campaigns, the preeclampsia diagnostics market is set to contribute significantly to improving maternity care and outcomes, ensuring healthier futures for mothers and their babies.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 148 |
| Forecast Period | 2022 – 2029 |
| Estimated Market Value (USD) in 2022 | $1.01 Billion |
| Forecasted Market Value (USD) by 2029 | $1.21 Billion |
| Compound Annual Growth Rate | 2.6% |
| Regions Covered | Global |
Companies Featured
- Thermo Fisher Scientific
- BioMérieux SA
- Atlas Medical
- Quidel Corporation
- Swiss Precision Diagnostics (SPD) GmbH
- NG BIOTECH SAS
For more information about this report visit https://www.researchandmarkets.com/r/40te9
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Preeclampsia Diagnostics Market
